Description of the active substance:
This information is a reference and it is not enough that the drug was prescribed by a doctor. .
Regulator of calcium and phosphorus metabolism. The chemical structure is close to ergocalciferol (vitamin D 2 ). Increases the permeability of the intestinal epithelium for calcium and phosphorus. Regulates the mineralization of bone tissue, as well as the process of mobilizing calcium from bone tissue. Increases the excretion of inorganic phosphates by the kidneys.
Dihydrotachysterol is metabolized in the liver by hydroxylation to form an active metabolite of 25-hydroxydihydrotachysterol.
Hypoparathyroidism (idiopathic and postoperative), pseudohypoparathyroidism, tetany (muscular convulsions caused by hypocalcemia), bone diseases due to vitamin D deficiency.
When administered orally, the daily dose is 0.25-1.5 mg. The frequency of application depends on the indications and concentrations of calcium in the blood and urine.
Adverse reactions are mainly due to hypercalcemia.
On the part of the digestive system: anorexia, nausea, vomiting, diarrhea; when used in high doses - biliary dyskinesia.
From the cardiovascular system: palpitation; rarely - heart rhythm disturbances.
From the side of metabolism: thirst, calcification of tissues.
From the side of the urinary system: with prolonged therapy - a violation of kidney function.
Other: pallor of the skin, headache.
Hypercalcemia, hypervitaminosis D, hypersensitivity to dihydrotachysterol and other preparations of vitamin D.
PREGNANCY AND LACTATION
If pregnancy is necessary, pregnancy should carefully weigh the intended benefit of treatment for the mother and the potential risk to the fetus.
Dihydrotachysterol is excreted in breast milk and can cause hypercalcemia in the infant.
Use with caution in patients with urolithiasis.
It is not recommended to use simultaneously with other vitamins of group D, calcium preparations, parathyroid agents.
Dihydrotachysterol should not be used in patients with allergic reactions to nuts (including peanuts).
When applied to the background of substitution therapy with thyroid hormones, a correction of the dosage regimen of dihydrotachysterol may be required.
With simultaneous use with thiazide diuretics, the risk of hypercalcemia increases; with colestyramine - possible disruption of absorption of dihydrotachysterol; with barbiturates, anticonvulsants, rifampicin, isoniazid - a decrease in the effectiveness of dihydrotachysterol is possible.
Against the background of the use of thyroid hormones, an increase in the clearance of dihydrotachysterol is possible.
Hypercalcemia caused by elevated doses of dihydrotachysterol may increase the toxic effects of cardiac glycosides.